Early and confident detection of disease progression is crucial for people living with fibrosing lung disease. Through our partnership with Brainomix, we want to help revolutionize the diagnostic landscape and thereby enable earlier treatment decisions. Learn more about the partnership below.
Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US. Michalis Papadakis: "There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and it can take many years for a patient to be diagnosed. "This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families." Read more about this partnership: ⬇ https://lnkd.in/eFhtvQhE Boehringer Ingelheim #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360